Glyn Edwards, interim Chief Executive of the BIA, said:
"Despite the hostile environment the BIA has great plans for 2012 to help members tackle the challenges around funding, taxation, patents, research regulation and patient access to life-enhancing therapies.
"To ensure that measures recently announced in the Life Sciences Strategy and Finance Bill 2012 meet the needs of our members, the BIA must have a strong, unified voice to continue to work with government and the regulators.
"Alongside our stakeholder engagement the BIA also provides a range of member services and sector-leading events which provide the opportunity for members to learn from the experience of experts, provide input into our engagement activities and to network with their peers."
For further information, please contact Robert Winder, Communications Manager, 020 7630 2191; mobile 07825 942 934.
BioIndustry Association
Founded over 20 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to www.bioindustry.org
